Item 2.02 Results of Operations and Financial Condition. On May 13, 2025, NeuroOne Medical Technologies Corporation (the “ Company”) issued a press release announcing its financial results for the fiscal quarter ended March 31, 2025. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K (this “ Current Report”) and is incorporated herein by reference.

Item 7.01 Regulation FD Disclosure On May 13, 2025, the Company posted an updated corporate presentation to its website at https://nmtc1. com/investors, which the Company may use from time to time in communications or conferences. A copy of the corporate presentation is attached as Exhibit 99.2 to this Current Report. This Current Report and Exhibit 99.2 hereto contain forward-looking statements within the meaning of the federal securities laws. These forward-looking statements are based on current expectations and are not guarantees of future performance. Further, the forward-looking statements are subject to the limitations listed in Exhibit 99.2 and in the other reports of the Company filed with the Securities and Exchange Commission, including that actual events or results may differ materially from those in the forward-looking statements. In accordance with General Instruction B.2. of Form 8-K, the information contained in Item 2.02 and this Item 7.01 of this Current Report, including Exhibits 99.1 and 99.2 hereto, is furnished pursuant to Items 2.02 and 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing. The Company’s submission of this Current Report shall not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated May 13, 2025. ─────────────────────────────────────────────────────────────────────────────────────────── 99.2 Corporate Presentation, dated May 2025. 104 Cover Page Interactive Data File (embedded with Inline XBRL document). SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEUROONE MEDICAL TECHNOLOGIES CORPORATION Dated: May 13, 2025 By: /s/ David Rosa David Rosa Chief Executive Officer